Herpes Zoster Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Herpes Zoster pipeline constitutes 18+ key companies continuously working towards developing 20+ Herpes Zoster treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Herpes Zoster Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Zoster Market.

Some of the key takeaways from the Herpes Zoster Pipeline Report:

* Companies across the globe are diligently working toward developing novel Herpes Zoster treatment therapies with a considerable amount of success over the years.
* Herpes Zoster companies working in the treatment market are CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others, are developing therapies for the Herpes Zoster treatment

* Emerging Herpes Zoster therapies in the different phases of clinical trials are- VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others are expected to have a significant impact on the Herpes Zoster market in the coming years.
* In January 2024, Jiangsu Recbio Technology, headquartered in China, has reported encouraging findings from its initial human trial of a shingles vaccine. This trial assessed REC610, an innovative adjuvanted recombinant shingles vaccine, in comparison to GSK's Shingrix. REC610 aims to stimulate the generation of significant quantities of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies, with the goal of preventing shingles among individuals aged 40 and older.
* In December 2022, Jiangsu Recbio Technology Co., Ltd. disclosed that they have secured clinical trial authorization for their innovative adjuvanted recombinant shingles vaccine, REC610, from the Philippines' Food and Drug Administration.

Herpes Zoster Overview

Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation ofvaricella-zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection withVZV before in life. VZV is explicitly a human virus that belongs to the -herpes virus family

Get a Free Sample PDF Report to know more about Herpes Zoster Pipeline Therapeutic Assessment-

delveinsight.com/report-store/herpes-zoster-pipeline-insight [http://delveinsight.com/report-store/herpes-zoster-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Herpes Zoster Drugs Under Different Phases of Clinical Development Include:

* VZV Vaccine: CPL Biologics
* Herpes Zoster vaccine: EuBiologics
* mRNA-1468: Moderna
* GLS5100: Gene One Life Science
* Z-1018: Dynavax Technologies Corporation
* EG-HZ: EyeGene
* CRV101: Curevo Inc
* Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Herpes Zoster Route of Administration

Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Herpes Zoster Molecule Type

Herpes Zoster Products have been categorized under various Molecule types, such as

* Oligonucleotide
* Peptide
* Small molecule

Herpes Zoster Pipeline Therapeutics Assessment

* Herpes Zoster Assessment by Product Type
* Herpes Zoster By Stage and Product Type
* Herpes Zoster Assessment by Route of Administration
* Herpes Zoster By Stage and Route of Administration
* Herpes Zoster Assessment by Molecule Type
* Herpes Zoster by Stage and Molecule Type

DelveInsight's Herpes Zoster Report covers around 20+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Herpes Zoster product details are provided in the report. Download the Herpes Zoster pipeline report to learn more about the emerging Herpes Zoster therapies [https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Herpes Zoster Therapeutics Market include:

Key companies developing therapies for Herpes Zoster are - Viatris Inc., Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc., Apotex Inc., Pfizer Inc., Hetero Drug (Camber Pharmaceuticals, Inc.), Cipla Inc., and others.

Herpes Zoster Pipeline Analysis:

The Herpes Zoster pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Zoster with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Zoster Treatment.
* Herpes Zoster key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Herpes Zoster Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Zoster market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Herpes Zoster drugs and therapies [https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Herpes Zoster Pipeline Market Drivers

* Increasing awareness and high demand for shingles prevention, rising incidence of herpes zoster, increasing awareness and high demand for shingles prevention, favorable reimbursement and funding policies are some of the important factors that are fueling the Herpes Zoster Market.

Herpes Zoster Pipeline Market Barriers

* However, high cost of vaccines, lack of vaccine compliance and knowledge about Shingles prevention, logistical and storage barriers, side effects associated with the current treatment options and other factors are creating obstacles in the Herpes Zoster Market growth.

Scope of Herpes Zoster Pipeline Drug Insight

* Coverage: Global
* Key Herpes Zoster Companies: CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others
* Key Herpes Zoster Therapies: VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others
* Herpes Zoster Therapeutic Assessment: Herpes Zoster current marketed and Herpes Zoster emerging therapies
* Herpes Zoster Market Dynamics: Herpes Zoster market drivers and Herpes Zoster market barriers

Request for Sample PDF Report for Herpes Zoster Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Herpes Zoster Report Introduction

2. Herpes Zoster Executive Summary

3. Herpes Zoster Overview

4. Herpes Zoster- Analytical Perspective In-depth Commercial Assessment

5. Herpes Zoster Pipeline Therapeutics

6. Herpes Zoster Late Stage Products (Phase II/III)

7. Herpes Zoster Mid Stage Products (Phase II)

8. Herpes Zoster Early Stage Products (Phase I)

9. Herpes Zoster Preclinical Stage Products

10. Herpes Zoster Therapeutics Assessment

11. Herpes Zoster Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Herpes Zoster Key Companies

14. Herpes Zoster Key Products

15. Herpes Zoster Unmet Needs

16 . Herpes Zoster Market Drivers and Barriers

17. Herpes Zoster Future Perspectives and Conclusion

18. Herpes Zoster Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=herpes-zoster-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-cpl-biologics-eubiologics-moderna-gene-one-life-science-dynavax]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.